Results 101 to 110 of about 11,432,263 (339)

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

open access: yesMolecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche   +8 more
wiley   +1 more source

United States Army Discharge Certificate [PDF]

open access: yes, 1946
This certificate from the United States Army states that Bob Jones received an Honorable Discharge from his military service in April of 1946. He was a Technician Fourth Grade in the 3112nd Signal Service Battalion at the time of his discharge. Jones was
Nellis, E. B.
core   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner   +6 more
wiley   +1 more source

Business Pandemic Infuenza Planning Checklist [PDF]

open access: yes, 2005
credit is requested.businessChecklist.pdf: 206 downloads, before Oct.
United States Department of Health and Human Services
core   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

open access: yesMolecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková   +14 more
wiley   +1 more source

Patients\u27 Rights to Access their Medical Records: An Argument for Uniform Recognition of a Right of Access in the United States and Australia [PDF]

open access: yes, 1997
This Note addresses the issue of a patient\u27s right to access her own medical records in the United States and Australia. Part I discusses the background of a right of patient access to medical records through case law in the United States.
Rosenman, Hayley
core   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

open access: yesMolecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez   +5 more
wiley   +1 more source

Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study

open access: yesMolecular Oncology, EarlyView.
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima   +6 more
wiley   +1 more source

Germany and the United States: A Comparison of Support for Wind Energy [PDF]

open access: yes, 2016
Germany leads the world in per capita wind energy production and public acceptance for wind energy is very high compared to a lack of support observed in the United States. A comparative study delineates many reasons for this difference.
Terry, P. A. (Patricia)
core  

Home - About - Disclaimer - Privacy